Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Genmab collaborator GSK starts new ofatumumab Phase III study in rare skin disorder
Improved self-efficacy in persons with relapsing remitting multiple sclerosis after an intensive social cognitive wellness program with participation of support partners: a 6-months observational study.
Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS) (ALLEGRO)
Comprehending the inexplicable: qualitative accounts of black Caribbean and white british people severely affected by multiple sclerosis.
Ophthalmic Evaluations in Clinical Studies of Fingolimod (FTY720) in Multiple Sclerosis.
Amiloride HCI Tablets, USP 5 mg
Ustekinumab induction and maintenance therapy in refractory Crohn's disease.
Paediatric acquired demyelinating syndromes: incidence, clinical and magnetic resonance imaging features.
Protective Associations of HDL with Blood Brain Barrier Injury in Multiple Sclerosis Patients.
Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine).
Physiopathology of symptoms and signs in multiple sclerosis.
The NOX1/4 Inhibitor GKT136901 as Selective and Direct Scavenger of Peroxynitrite.
Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis.
Lodonal/LDN
Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.
Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 mg GA Depot in Subjects With RRMS
Materials for stem cell factories of the future.
Mapi Pharma granted United States patent covering glatiramer depot for multiple sclerosis
Endogenous retroviruses and multiple sclerosis--new pieces to the puzzle.
Laquinimod
Autoimmune myelopathies.
Sexual dysfunction ın multiple sclerosis: Gender differences.
Norovirus-related chronic diarrhea in a patient treated with alemtuzumab for chronic lymphocytic leukemia.
Intense immunosuppression in chronic progressive multiple sclerosis: the Kaiser study.
Neuronal NF-κB ablation does not influence neuro-axonal degeneration in experimental autoimmune demyelination.

Pages